Boiron (FRA:BON) 3-Year FCF Growth Rate : -16.50% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron 3-Year FCF Growth Rate?

Boiron's Free Cash Flow per Share for the six months ended in Dec. 2023 was €1.10.

During the past 12 months, Boiron's average Free Cash Flow per Share Growth Rate was -31.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -16.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 2.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Boiron was 144.70% per year. The lowest was -46.70% per year. And the median was 1.05% per year.

Competitive Comparison of Boiron's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Boiron's 3-Year FCF Growth Rate falls into.

Boiron 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Boiron (FRA:BON) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Boiron 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Boiron's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.